Biomarker profiles and changes from baseline in trastuzumab (T) refractory HER2-positive inflammatory breast cancer (IBC) that predict decreases in tumor burden from lapatinib (L) monotherapy. SPARC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results